New sequencing methods in lung cancer patient' tissue to predict response to immunotherapy
2018
Memorial Sloan Kettering Cancer Center, New York, USA
An urgent need exists to develop clinically practical tools to identify the subset of lung cancer patients most likely to derive clinical benefits from treatment based on immune checkpoint inhibitors (ICIs). In the present study, the researchers hypothesized that determining the tumor mutation burden by targeted Next Generation Sequencing may help predictions. 240 patients with lung cancer and treated with immune checkpoint blockade were profiled by targeted NGS. A subset of tumors from these patients was analyzed by another sequencing method called Whole Exome Sequencing (WES) to strengthen the analysis. The data showed that elevated TMB improved the likelihood of benefit to treatment by immune checkpoint blockade. Interestingly, TMB did not correlate with the expression of main markers for use of immune checkpoint blockade; the incorporation of both variables should be introduced into multivariable predictive models to generate greater predictive power.
Molecular determinants of response to anti–Programmed Cell Death (PD)-1 and anti–Programmed Death-Ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted Next-Generation Sequencing
Matthew D. Hellmann
Added on: 09-17-2021
[1] https://ascopubs.org/doi/10.1200/JCO.2017.75.3384[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
